42o words (source - 2% match) vs. 479 words (mine - 1% match) Have you ever had a lingering itch? An itch that just wouldn't go away, no matter what…
Currently, there are no FDA-approved treatments designed for cognitive impairment related to Huntington’s disease. However, to improve the lives of those affected, additional research and therapeutic development are urgently…
In early October 2023, the clinical-stage biotechnology company AnaptysBio, Inc. shared, via a news release, that positive top-line results were available from the Phase 3 GEMINI-1 study. Within the…
Both methotrexate and cyclosporin may be leveraged to treat severe atopic dermatitis in children. But is one treatment more effective than the other? Researchers attempted to answer this question…
The 2023 World Conference on Lung Cancer took place from September 9-12 this year. During the conference, stakeholders came together to discuss novel research, emerging trends, and other needs…
Advancing patient outcomes hinges on the development of targeted treatments, particularly in conditions with grim prognoses such as small cell lung cancer (SCLC), which typically has a life expectancy…
In a recent report from Dermatology Times, Acelyrin has disclosed the disappointing outcome of its experimental therapy, izokibep, which failed to meet the primary endpoint in a phase 2b/3 clinical…
Currently, neoadjuvant chemotherapy is a key approach in treating ovarian cancer. Neoadjuvant chemotherapy aims to reduce tumor size, allowing for surgical removal following three cycles of chemotherapy. Additional chemotherapy…
Clostridioides difficile (C. diff) is a contagious bacterium that causes colon infections. People with C. diff infections (CDI) experience various symptoms, such as diarrhea and colonic inflammation, and in…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
The ongoing Phase 2 PAVIA clinical study is evaluating EYP-1901 as a potential therapeutic intervention for people with moderately severe to severe non-proliferative diabetic retinopathy; the DAVIO 2 study is…
As reported by MSN, researchers have discovered that the blood vessels feeding aggressive brain tumors can be useful. The blood vessels have receptors that contain nanoparticles that can be…
The 2023 Annual Meeting of the Myotonic Dystrophy Foundation took place from September 7-9 this year. During the meeting, stakeholders gathered in the nation's capital to discuss research, trends,…
Also known as Richter’s Transformation, Richter syndrome is a rare and aggressive complication of chronic lymphocytic leukemia (CLL). When someone develops Richter syndrome, their CLL can transform into another rare…
The U.S. FDA has approved two treatments for people living with idiopathic pulmonary fibrosis (IPF). These therapies—Esbriet (pirfenidone) and Ofev (nintedanib)—both work to reduce fibrosis, or scarring, in the…
In Jordyn Sava's reporting from Targeted Oncology, readers learn that the U.S. Food and Drug Administration (FDA) granted clearance to a global Phase 3 study. This means that the…
The Phase 2 EXHALE-1 clinical trial, initiated by clinical-stage biotechnology company Areteia Therapeutics, Inc. ("Areteia"), sought to understand how safe, effective, and well-tolerated dexpramipexole was in reducing symptoms of…
A Phase 2 clinical study found TAK-994 to be relatively effective in reducing symptoms like excessive daytime sleepiness (EDS) and cataplexy (sudden, uncontrollable muscle weakness often triggered by strong…
The Cholangiocarcinoma Foundation has recently released a white paper titled “Cross-over arms in oncology clinical trials: An important consideration for patients.” This paper highlights a non-traditional clinical trial approach that…
Recent results are available from the dose escalation portion of the Phase 1 ANTLER study. In reporting from Targeted Oncology, Jordyn Sava shares that the study included 16 participants living…
An estimated 25% of children globally are affected by atopic dermatitis; you may known this skin condition by its more colloquial name, "eczema." Often manifesting by five years old, atopic…
According to a story from Clinical Trials Arena, the pharmaceutical company Takeda recently released findings from its phase II clinical trial. This trial was evaluating the company's investigational drug TAK-994…
Prior to launching a clinical trial, the FDA must clear an Investigational New Drug (IND) application. This allows the drug to be distributed across state lines, which is important…
In a late July 2023 news release, global healthcare company Grifols shared that positive topline data was now available from a Phase 4 clinical study evaluating XEMBIFY (immune globulin…
Each year, there are less than 600 new cases of papillary craniopharyngioma (PCP) diagnosed within the United States. While PCP typically has a good prognosis with treatment, treatment is…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
